Monopar Therapeutics Inc. (MNPR), Thursday announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 trial, confirming the compound's tumor-targeting ability in humans.
The study showcased that MNPR-101, a humanized monoclonal antibody, targets cancers expressing the urokinase plasminogen activator receptor such as breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.
Moreover, the biotechnology company has received a clearance in Australia to commence an MNPR-101-Lu Phase 1 therapeutic clinical trial, which is set to launch in the fourth quarter.
Currently, Monopar's stock is surging 65.38 percent, to $3.98 over the previous close of $2.40 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.